PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Progress in the treatment of urogenital tumors
Article published in Urologia Polska 2006/59/3.

authors

Kornelia Tomaszewska 1, Janina Markowska 1, Anna Markowska 2, Radosław Mšdry 1, Zbigniew Szewierski 1
1 Klinika Onkologii Akademii Medycznej w Poznaniu
2 Klinika Perinatologii i Chorób Kobiecych Akademii Medycznej w Poznaniu

keywords

angiogenesis, antyangiogenic therapy, gene therapy, monoclonal antibody therapy

summary

Introduction. Better understanding of molecular mechanisms proceeding during neoplasmatic transformation enabled introduction of some new treatment methods in oncology. Some cytostatic drugs used in cancer treatment are both antiangiogenic agents and cytostatic agents for neoplastic cells. Despite of interrelationships and interactions the cancer treatment strategy, for practical reasons, was divided into three main groups: antiangiogenic therapy, gene therapy and therapy with use of monoclonal antibodies.
Objective. We aimed to discuss new strategies in cancer treatment.
Material and method. Theoretical analysis based on medical literature and Internet databases.
Results. Antiangiogenic, gene and monoclonal antibodies in cancer treatment were presented.

references

  1. See HT, Kavanagh J, Hu W, Bast RC Jr: Target therapy for epithelial ovarian cancer: Curent status and future prospects. J Cancer 2003, 13, 701-734.
  2. Eisen T, Boshoff C, Mak J et al: Continous low dose thalidomide: a phase study in advanced melonoma, renal cell, ovarian an breast cancer. Br J Cancer 2000, 82 (4), 812.
  3. Yu JL, Rak JW Coomber BL et al: Effect on p53 status of tumor reponse to aggiogenic therapy. Science 2002, 295, 1526-1530.
  4. Bałan BJ: Angiogeneza – problem na miarę XXI wieku. Nowa Med – Pulmonol 2000, 4, 100.
  5. Skopińska-Różewska E, Skopiński P: Modulacja procesów angiogenezy – nowy kierunek w immunologii klinicznej. Terapia 2001, 3, 2.
  6. Kabacińska I: Angiogeneza – przegląd badań nad angiogenezą, stan wiedzy i możliwości terapeutyczne. www.kardiolog.pl (wprowadzono do archiwum 13.12.2004) Polski Portal Kardiologiczny.
  7. Scappaticci FA: Mechanisms and future directions for angiogenesis – based cancer therapies. Review article. J Clin Oncol 2002, 20, 3906-3925.
  8. Olbryt M, Szala S: Białkowe inhibitory angiogenezy w terapii nowotworów. Wsp Onkol 2005, 9, 2, 48-53.
  9. Griffioen AW, Molema G: Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Reviews 2000, 52, 237-268.
  10. Cavallo T et al: Tumor angiogenesis. J Cell Biol 1972, 54, 408-420.
  11. Markowska J, Szala S: Inhibitors of angiogenesis in therapy of ovarian cancers. Eur J Gynaec Oncol 2004, 5, 562-567.
  12. Coomber BL, Yu JL, Fathers KE et al: Angiogenesis and the role of epigenetics in metastasis. Clin Exp Metastasis 2003, 20, 215.
  13. Gordon MS: Novel antiangiogenic therapies for renal cell cancer. Clin Cancer Res 2004, 10, 6377-6381.
  14. Escuder B, Szczylik C, Eisen T et al: Randomized phase III trial of the Raf kinase and VEGF inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005, 23, 16S, 380S.
  15. Rini B, Rixe O, Bukowski R et al: AG-013736, a multi target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 of cytokine-refractory, metastatic, renal cell cancer (RCC). J Clin Oncol 2005, 23, 16S, 380.
  16. Rosano L, Spinella F, Salami D et al: Therapeutic targeting of the endothelin a receptor in human ovarian cancer carcinoma. Cancer Res 2003, 63, 2447-2453.
  17. Narocki S, Mackiewicz A: Terapia biologiczna nowotworów – pierwsze sukcesy kliniczne i perspektywy na przyszłość. Nowa Med – Onkol 2000, V, 10, 39-44.
  18. Sochanik A, Szala S: Perspektywy wykorzystania syntetycznych wirusów w terapii genowej. Post Bioch 2000, 3, 219-226.
  19. Latf F, Tory K, Gnarra JR et al: Identifcation of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260, 1317-1320.
  20. Schmidt L, Duh F-M, Chen F et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Gen 1997, 16, 68-73.
  21. Schmidt L, Junker K, Weirich G et al: Two North American families with hereditary papillary renal carcinoma and identical nevel mutations in the MET proto-oncogene. Cancer Res 1998, 58, 1719-1722.
  22. Toroet J, Duray PH, Glenn GM et al: Birt-Hogg-Dube syndrome: A novel marker of kidney neoplasia. Arch Dermatol 1999, 135, 1195-1202.
  23. Pavlovich CP, Hewitt S, Walther MM et al: Renal tumors in the Birt-Hogg-Dube Syndrome. Am J Surg Pathol 2002, 26, 1542-1552.
  24. Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol 2003, 170, 2163-2172.
  25. Kohler G et al: Continuous cultures of fused cells secreting antibody of predefined specifity. Nature 1975, 6, 495-497
  26. Berinstein NL et al: Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998, 9, 995-1001.
  27. Baselga J et al: Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998, 58, 2825-2831.
  28. Hamann PR et al: Gemtuzumab ozogamicin, a potent and selective anti CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjung Chem 2002, 13, 1, 47-58.
  29. Bryd JC et al: Novel therapies for chronic lymphocytic leukemia in the 21st entury. Semin Oncol 2000, 27 (5), 587-597.
  30. Wiseman GA et al: Phase I/II 90Y Zevalin TM (90yttrium ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000, 27, 7, 766-777.
  31. http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=259
  32. http://www.fda.gov/bbs/topics/NEWS/2004/NEW01024.html
  33. http://www.fda.gov/fdac/features/2004/304_cancer.html
  34. Nicodemus CF: Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies. Expert Review of Vaccines 2002, 1, 1, 35-48.
  35. Rowinsky EK, Schwarz GH, Gollob JA et al: Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer. Journal of Clinical Oncology 2004, 22, 15, 3003-3015.
  36. Motzer RJ, Amato R, Todd M et al: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21 (1), 99-101.
  37. Yang JC, Haworth L, Sherry RM et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349, 427-434.
  38. Riedel F, Gotte K, Li M et al: EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol 2002, 21, 11-16.
  39. Hainsworth JD, Sosman JA, Spigel DA et al: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma. Proc Am Soc Clin Oncol 2004, 23, 381.

correspondence

Janina Markowska
Oddział Ginekologii Kliniki Onkologii AM
ul. Łąkowa 1/2
61-878 Poznań
tel. (061) 854 90 16
korneliatomaszewska@wp.pl